Efficacy of Mizoribine (MZR) treatment for gastrointestinal symptoms in kidney transplant recipients using mycophenolate mofetil (MMF). - Open-label, multicenter, randomized, controlled trial –
Not Applicable
- Conditions
- Kidney transplantation
- Registration Number
- JPRN-UMIN000008649
- Lead Sponsor
- Tokyo Women Medical University, Dep. Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1.currently undergoing acute rejection 2.positive for DSA 3.serum creatinine level of less than 3mg/dL 4.a severe infection other than viral infection 5.white blood cell counts of less than 3,000/mm3 6.pregnant women and women suspected of being pregnant 7.aged 19 or younger 8.considered inappropriate by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of GSRS results between the 1st day and a month later.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie MZR's efficacy in mitigating MMF-induced gastrointestinal toxicity post-kidney transplant?
How does MZR compare to standard anti-GI therapies like proton pump inhibitors in kidney transplant recipients on MMF?
Are specific biomarkers associated with improved GI symptom resolution when switching from MMF to MZR post-transplant?
What are the potential adverse events of MZR therapy in immunosuppressed kidney transplant patients and how are they managed?
What combination strategies with MZR are being explored to enhance GI symptom management in MMF-treated renal transplant recipients?